#	Pagina
attuale pagina	/open-h2020/projects/196682/index.html

Opendata, web and dolomites

NANOTAM

Development and Evaluation of Nanomedicines for Cancer Treatment through Immunomodulation: Targeting Tumor-Associated Macrophages

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NANOTAM project word cloud

Explore the words cloud of the NANOTAM project. It provides you a very rough idea of what is the project "NANOTAM" about.

treatment tissues peptide re lasting anti biodegradable vitro immune involve resistance progress loaded ultimately prognosis patients nrp1 nanostructures back chronic microenvironment compounds tlr7 inflammation manipulate tumoural linking vivo immunomodulatory lyp event polysaccharides polarization containing lymphatic kill receptors poor pro therapeutic drugs outcomes tns series direct affinity immunosuppressive satisfactory chitosan therapies residues chemical pharmacological mannose nanomedicines effect invasion tam immunostimulatory suppression verify infiltration functionalized conveniently activators acid expressed macrophages host surface cancer optimally tumour cs shown density dominant educate chemotherapeutic correlated effectiveness strategies metastasis hyaluronic switching tested tumours

Project "NANOTAM" data sheet

The following table provides information about the project.

Coordinator	HUMANITAS MIRASOLE SPA Organization address address: VIA MANZONI 56 city: ROZZANO (MI) postcode: 20100 website: www.humanitas.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	168˙277 €
EC max contribution	168˙277 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2015
Duration (year-month-day)	from 2015-05-20 to 2017-05-19

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	HUMANITAS MIRASOLE SPA HUMANITAS MIRASOLE SPA Organization address address: VIA MANZONI 56 city: ROZZANO (MI) postcode: 20100 website: www.humanitas.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROZZANO (MI))	coordinator	168˙277.00

Map

Project objective

This project is focused on the development of novel nanomedicines effective in targeting the immunosuppressive, pro-tumoural, Tumour-Associated Macrophages (TAM) with the aim to manipulate the host’s immune system and improve anti-tumour responses. In most patients, chronic inflammation and immune suppression are the dominant effects in the tumour microenvironment. The infiltration of TAM in tumour tissues has been shown to support tumour growth, invasion and metastasis. Indeed, high density of TAM in tumours is correlated with resistance to therapies and poor prognosis. These findings establish TAM as promising targets of future anti-tumour therapies.

Here, we aim to design a series of Therapeutic Nanostructures (TNs), containing immunomodulatory or chemotherapeutic compounds, and conveniently functionalized, in order to target and re-educate or kill the TAM. These novel TNs will be composed of biodegradable polysaccharides, i.e. chitosan (CS) or hyaluronic acid (HA), and will be functionalized, with the aim to develop a series of “targeting” strategies to optimally reach TAM in vivo. These strategies involve the chemical linking of: (i) mannose residues expected to direct the TNs to the mannose receptors, highly expressed on the surface of TAM or (ii) the tumour lymphatic-specific peptide (LyP-1), known to have affinity towards NRP1 on TAM. The nanomedicines (TNs) will be loaded with pharmacological activators of TLR7 aimed to re-educate TAM into immunostimulatory anti-tumour macrophages. In the event that re-polarization of TAM is not satisfactory, or its effect is not long lasting in vivo, TNs will be loaded with chemotherapeutic drugs able to kill TAM. The TNs will be tested in vitro and in vivo to verify their effectiveness in switching back the pro-tumoural properties of TAM and their effect on tumour growth. We expect that this approach will enable greater progress in the treatment of tumours and ultimately lead to improved outcomes for cancer patients.

Publications

List of publications.
year	authors and title	journal	last update
2015	Fernando Torres AndÃ³n, MarÃa JosÃ© Alonso Nanomedicine and cancer immunotherapy â€“ targeting immunosuppressive cells published pages: 656-671, ISSN: 1061-186X, DOI: 10.3109/1061186X.2015.1073295	Journal of Drug Targeting 23/7-8	2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOTAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOTAM" are provided by the European Opendata Portal: CORDIS opendata.